Author

J. D. Lang

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 4 Research Focus:drug response / drug discovery· 3 Research Focus:cell type annotation· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

A. N. Karnezis· 3 shared B. E. Weissman· 3 shared D. G. Huntsman· 3 shared E. A. Raupach· 3 shared J. M. Trent· 3 shared K. A. Orlando· 3 shared P. Pirrotte· 3 shared S. J. Facista· 3 shared

Activity by Year

2017-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. N. Karnezis

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Landscape of super-enhancers in small cell carcinoma of the ovary, hypercalcemic type and efficacy of targeting with natural product triptolide

J. D. Lang, W. Selleck, S. Striker, N. A. Hipschman, R. Kofman, A. N. Karnezis, F. K. Kommoss, F. Kommoss, J. R. Wendt, S. J. Facista, W. P. Hendricks, K. A. Orlando, P. Pirrotte, E. A. Raupach, V. L. Zismann, , J. M. Trent

This paper identifies super-enhancer activity in SCCOHT driven by SMARCA4 loss and shows triptolide effectively inhibits tumor growth by targeting TFIIH at super-enhancers.

iScience · Feb 1, 2025Peer-reviewedCancer Biology

CD8+ cells and small viral reservoirs facilitate post-ART control of SIV in Mauritian cynomolgus macaques

O. E. Harwood, L. M. Matschke, R. V. Moriarty, A. J. Balgeman, A. J. Weaver, A. L. Ellis-Connell, A. M. Weiler, L. C. Winchester, C. V. Fletcher, T. Friedrich, B. F. Keele, D. H. O'Connor, J. D. Lang, M. R. Reynolds, S. L. O'Connor

bioRxiv · Mar 1, 2023 · PreprintImmunology

The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer

R. Soldi, T. Ghosh Halder, A. Weston, T. Thode, K. Drenner, R. Lewis, M. R. Kaadige, S. Srivastava, S. Daniel Ampanattu, R. Rodriguez del Villar, J. D. Lang, H. Vankayalapati, B. Weissman, J. Trent, W. Hendricks, S. Sharma

This study shows that the LSD1 inhibitor SP-2577 enhances anti-tumor immunity and PD-L1 expression in SWI/SNF-mutated ovarian cancer models.

bioRxiv · Jan 10, 2020Cancer Biology

Novel functional insights revealed by distinct protein-protein interactions of the residual SWI/SNF complex in SMARCA4-deficient small cell carcinoma of the ovary, hypercalcemic type

E. A. Raupach, K. Garcia-Mansfield, R. Sharma, A. M. Hegde, V. David-Dirgo, Y. Wang, C. Young Shin, L. V. Tao, S. J. Facista, R. Moore, J. D. Lang, V. L. Zismann, K. A. Orlando, M. Spillman, A. N. Karnezis, , P. Pirrotte

This study identifies distinct protein-protein interactions of the residual SWI/SNF complex in SMARCA4-deficient SCCOHT cell lines, revealing altered functional consequences and potential synthetic lethal targets.

bioRxiv · Oct 6, 2019 · PreprintCancer Biology

Ponatinib shows potent antitumor activity in small cell carcinoma of the ovary hypercalcemic type (SCCOHT) through multi-kinase inhibition

J. D. Lang, W. P. D. Hendricks, H. Yin, J. Kiefer, P. Ramos, R. Sharma, P. Pirrotte, E. A. Raupach, C. Sereduk, N. Tang, W. S. Liang, M. Washington, S. J. Facista, V. L. Zismann, E. M. Cousins, , J. M. Trent

This paper identifies ponatinib as a potent treatment for SCCOHT by inhibiting multiple kinases in preclinical models.

bioRxiv · Jul 6, 2017Cancer Biology